Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 68Ga-R10602 injection
68Ga-R10602 · 1 trial · 3 indications
Number of participants with adverse events as assessed by NCI-CTCAE v5.0, including grade
Number of participants with serious adverse events
Number of participants with clinically significant change in clinical laboratory parameters
| Arm | Type | Description |
|---|---|---|
| 68Ga-R10602 Imaging Optimization Portion (Cohort 1) | OTHER | 68Ga-R10602 injection at pre-defined dose levels. PET/CT imaging at pre-defined timepoints. |
| 68Ga-R10602 Imaging Confirmation Portion (Cohort 2) | OTHER | 68Ga-R10602 injection at the selected dose level. PET/CT imaging at a single timepoint. |
| Name | Type | Description |
|---|---|---|
| 68Ga-R10602 injection | DRUG | 68Ga-R10602 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions in hormone receptor positive breast cancer |
Inclusion Criteria: 1. Breast Cancer Eligibility: * Population 1: Pathologically confirmed ER and/or PR positive, locoregionally recurrent or metastatic breast cancer that is refractory to endocrine therapy (progression on at least one line of endocrine therapy and determined by the investigato...
68Ga-R10602 is an investigational small molecule being developed by Crinetics Pharmaceuticals, Inc. (ticker CRNX). It is being studied in oncology for locoregionally recurrent hormone-receptor positive breast cancer. It is a Phase 1 agent and has not been approved by the FDA.
68Ga-R10602 is being studied for locoregionally recurrent hormone-receptor positive breast cancer, as well as metastatic hormone receptor positive breast cancer and hormone receptor positive breast adenocarcinoma. It is an investigational agent in Phase 1 development and is not approved for any use.
68Ga-R10602 is developed by Crinetics Pharmaceuticals, Inc., which trades under the ticker CRNX. The company is the sponsor of the clinical program evaluating the agent in hormone-receptor positive breast cancer.
68Ga-R10602 is in Phase 1 development. The single Phase 1 study of the agent has been completed, and the drug remains investigational. It has not been approved by the FDA for any indication.
68Ga-R10602 has been evaluated in one Phase 1 trial, NCT06745804, titled Study of 68Ga-R10602. That trial enrolled 27 participants in the United States and is now completed. It studied locoregionally recurrent hormone-receptor positive breast cancer, metastatic hormone receptor positive breast cancer, and hormone receptor positive breast adenocarcinoma.
Yes. 68Ga-R10602 injection is another name for 68Ga-R10602, the investigational small molecule developed by Crinetics Pharmaceuticals, Inc. (CRNX) for hormone-receptor positive breast cancer. Both names refer to the same Phase 1 agent.